SCHEMBL5679031

SCHEMBL5679031

CC(=O)N[C@H]1C(OP(=O)(O)O)O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.61

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
THRB P10828 1/20 0.61
MAPK1 P28482 2/20 0.58
CD69 Q07108 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
P2RY14 Q15391 1/20 0.48
P2RY2 P41231 1/20 0.48
P2RY4 P51582 1/20 0.48
P2RY6 Q15077 1/20 0.48
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29013440 1.00 ALDH1A1 (0.61) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL18700558 1.00 ALDH1A1 (0.61) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL29735890 1.00 ALDH1A1 (0.61) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL18710872 1.00 ALDH1A1 (0.61) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL7152633 1.00 ALDH1A1 (0.61) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL15334201 1.00 ALDH1A1 (0.61) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL317138 1.00 ALDH1A1 (0.61) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL22410446 1.00 ALDH1A1 (0.61) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL20552181 1.00 ALDH1A1 (0.61) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL1521416 1.00 ALDH1A1 (0.61) ALDH1A1THRBMAPK1CD69SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702138-A1 PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL Inbiose N.V. (BE) 2026-03-04 EP claimed
WO-2025072741-A1 PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-03 WO claimed
WO-2025051985-A1 NEW METHOD FOR SYNTHESISING PHOSPHATE OLIGOSACCHARIDES OR PHOSPHATE POLYSACCHARIDES SWEETECH (FR) 2025-03-13 WO claimed
WO-2024223815-A1 PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL INBIOSE N.V. (BE) 2024-10-31 WO claimed
EP-4256049-A2 MODULAR GLYCAN PRODUCTION WITH IMMOBILIZED BIONANOCATALYSTS ZYMtronix Catalytic Systems, Inc. (US) 2023-10-11 EP claimed
EP-4192946-A1 CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES Inbiose N.V. (BE) 2023-06-14 EP claimed
EP-4143328-A1 ENZYME CASCADES BASED ON SUCROSE SYNTHASE AND PYROPHOSPHORYLASE FOR CONVERSION OF ADP TO ATP Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen (DE) 2023-03-08 EP claimed
EP-4045518-A1 PRODUCTION OF BIOPRODUCT IN A HOST CELL Inbiose N.V. (BE) 2022-08-24 EP claimed
WO-2022119982-A2 MODULAR GLYCAN PRODUCTION WITH IMMOBILIZED BIONANOCATALYSTS ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) 2022-06-09 WO claimed
US-11136608-B2 Microbial fermentation method for production of n-acetyl-d-glucosamine and/or d-glucosamine salt SUN LAN (CN) 2021-10-05 US claimed
US-20200308615-A1 METHOD FOR PRODUCING N-ACETYL-D-GLUCOSAMINE AND/OR D-GLUCOSAMINE SALT BY MICROBIAL FERMENTATION SUN LAN (CN) 2020-10-01 US claimed
EP-3441473-A1 METHOD FOR PRODUCING N-ACETYL-D-GLUCOSAMINE AND/OR D-GLUCOSAMINE HYDROCHLORIDE BY MICROBIAL FERMENTATION Sun, Lan (CN) 2019-02-13 EP claimed
EP-2566953-B1 METHODS FOR CONTROL OF FLUX IN METABOLIC PATHWAYS THROUGH ENZYME RELOCATION GREENLIGHT BIOSCIENCES INC (US) 2019-01-02 EP claimed
EP-4743567-A1 CELLULAR PRODUCTION OF LACTO-N-TRIOSE (LN3)-CONTAINING OLIGOSACCHARIDES Inbiose N.V. (BE) 2026-05-20 EP disclosed
EP-4731778-A2 SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES Inbiose N.V. (BE) 2026-04-29 EP disclosed
EP-4702138-A1 PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL Inbiose N.V. (BE) 2026-03-04 EP disclosed
US-20180169015-A1 LIPID-DERIVED NEUTRAL NANOPARTICLES SHIRE HUMAN GENETIC THERAPIES, INC. 2018-06-21 US disclosed
US-20180169016-A1 LIPID-DERIVED NEUTRAL NANOPARTICLES SHIRE HUMAN GENETIC THERAPIES, INC. 2018-06-21 US disclosed
CN-106573962-A Novel glycan conjugates and uses thereof 中央研究院 2017-04-19 CN disclosed
US-20060141546-A1 Bacterial test method by glycated label binding SIEMENS HEALTHCARE DIAGNOSTICS INC. 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180169015-A1 LIPID-DERIVED NEUTRAL NANOPARTICLES PHOSPHO1, LPAR6, PLIN3 ALDH1A1 4447/4885THRB 3379/4885MAPK1 4125/4885
US-20180169016-A1 LIPID-DERIVED NEUTRAL NANOPARTICLES PHOSPHO1, LPAR6, PLIN3 ALDH1A1 4447/4885THRB 3379/4885MAPK1 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.